CN116333088A - 包含c-c基序趋化因子22（ccl22）或其片段的疫苗组合物 - Google Patents

包含c-c基序趋化因子22（ccl22）或其片段的疫苗组合物 Download PDF

Info

Publication number
CN116333088A
CN116333088A CN202310505999.4A CN202310505999A CN116333088A CN 116333088 A CN116333088 A CN 116333088A CN 202310505999 A CN202310505999 A CN 202310505999A CN 116333088 A CN116333088 A CN 116333088A
Authority
CN
China
Prior art keywords
ccl22
seq
cells
peptide
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310505999.4A
Other languages
English (en)
Chinese (zh)
Inventor
梅斯·哈尔德·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Herlev Hospital Region Hovedstaden
Original Assignee
Herlev Hospital Region Hovedstaden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herlev Hospital Region Hovedstaden filed Critical Herlev Hospital Region Hovedstaden
Publication of CN116333088A publication Critical patent/CN116333088A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202310505999.4A 2015-09-16 2016-09-16 包含c-c基序趋化因子22（ccl22）或其片段的疫苗组合物 Pending CN116333088A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201570591 2015-09-16
DKPA201570591 2015-09-16
PCT/DK2016/050301 WO2017045691A1 (en) 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
CN201680067136.1A CN108472345B (zh) 2015-09-16 2016-09-16 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680067136.1A Division CN108472345B (zh) 2015-09-16 2016-09-16 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物

Publications (1)

Publication Number Publication Date
CN116333088A true CN116333088A (zh) 2023-06-27

Family

ID=57123753

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310505999.4A Pending CN116333088A (zh) 2015-09-16 2016-09-16 包含c-c基序趋化因子22（ccl22）或其片段的疫苗组合物
CN201680067136.1A Active CN108472345B (zh) 2015-09-16 2016-09-16 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680067136.1A Active CN108472345B (zh) 2015-09-16 2016-09-16 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物

Country Status (8)

Country Link
US (3) US11298413B2 (enExample)
EP (1) EP3349785A1 (enExample)
JP (1) JP6924747B2 (enExample)
CN (2) CN116333088A (enExample)
AU (1) AU2016322506B2 (enExample)
HK (1) HK1257448A1 (enExample)
IL (1) IL257940B (enExample)
WO (1) WO2017045691A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6924747B2 (ja) * 2015-09-16 2021-08-25 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃ−ｃモチーフケモカイン２２（ｃｃｌ２２）またはこのフラグメントを含むワクチン組成物
JP2021515797A (ja) * 2018-03-15 2021-06-24 アトッサ・セラピューティクス・インコーポレイテッド 免疫反応誘導のインサイツ方法
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
US20230256069A1 (en) * 2020-07-30 2023-08-17 Centro De Inmunología Molecular Use of epidermal growth factor depleting agents in the treatment of chronic obstructive pulmonary disease
WO2024168311A2 (en) * 2023-02-09 2024-08-15 The Brigham And Women’S Hospital, Inc. Autonomous gene circuits for therapy release

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US7018627B1 (en) * 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
PL318594A1 (en) 1995-06-07 1997-06-23 Icos Corp Chemokine and analogues thereof originating from macrophages
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
AU5617900A (en) * 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
US8563476B2 (en) * 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
EP2260846B1 (en) * 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
EP2628749A3 (en) * 2006-06-20 2013-12-04 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Antimicrobial kinocidin compostions and methods of use
HRP20180282T1 (hr) 2008-04-17 2018-03-23 Io Biotech Aps Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
WO2011006029A1 (en) * 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
WO2011139738A2 (en) 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
LT2768524T (lt) 2011-10-17 2022-07-25 Io Biotech Aps Pd-l1 grindžiama imunoterapija
JP6523685B2 (ja) * 2012-01-03 2019-06-05 アメリカ合衆国 Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ
WO2014028644A1 (en) 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
CA2883711A1 (en) * 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
ES3011466T3 (en) 2013-04-18 2025-04-07 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10130454B2 (en) 2014-08-01 2018-11-20 Iowa State University Research Foundation, Inc. Vaccine delivery devices
JP6924747B2 (ja) 2015-09-16 2021-08-25 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃ−ｃモチーフケモカイン２２（ｃｃｌ２２）またはこのフラグメントを含むワクチン組成物

Also Published As

Publication number Publication date
IL257940A (en) 2018-05-31
US20190008939A1 (en) 2019-01-10
US20230241191A9 (en) 2023-08-03
EP3349785A1 (en) 2018-07-25
CN108472345A (zh) 2018-08-31
US12496333B2 (en) 2025-12-16
US20220280624A1 (en) 2022-09-08
IL257940B (en) 2022-08-01
AU2016322506A1 (en) 2018-04-12
JP2018528960A (ja) 2018-10-04
WO2017045691A9 (en) 2018-06-28
CA2998789A1 (en) 2017-03-23
US11298413B2 (en) 2022-04-12
CN108472345B (zh) 2023-05-23
WO2017045691A1 (en) 2017-03-23
AU2016322506B2 (en) 2023-02-09
AU2016322506A9 (en) 2018-12-06
NZ740930A (en) 2024-09-27
US20220339273A1 (en) 2022-10-27
JP6924747B2 (ja) 2021-08-25
HK1257448A1 (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
US12233103B2 (en) Indoleamine 2,3-dioxygenase based immunotherapy
US12496333B2 (en) Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
US11878053B2 (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CA2998789C (en) Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
HK1247114A1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination